Fig. 4. O-GlcNAcylation on Rab3A attenuates its inhibition on HCC metastasis.

a, b Transwell assays for Hep3B and PLC/PRF/5 cells with Rab3A and/or OGT level changes. c, d Transwell assays for Hep3B-shOGT and PLC/PRF/5-OGT stable cells treated with ST078925 (50 μM) or ST045849 (50 μM). e, f In vivo effect of Rab3A in intravenous metastasis model at fourth week after injection (n = 6 in each group). Representative images of lung-metastasis mice were shown on the left, and statistical data was shown on the right. g Correlation of Rab3A and/or OGT expression with vessel invasion in IHC cohort. h Kaplan–Meier analysis for overall survival of HCC patients from IHC cohort. i A tentative model describing the potential suppressive effects of O-GlcNAcylation on Rab3A. *p < 0.05, **p < 0.01, ***p < 0.001; NS, not significant